Physician profile
Christopher Fan
NPI 1922637768
$3,928.65
in general payments reported to CMS, 2019-2025
12 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2022: $146 · 2023: $1,051 · 2024: $1,233 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,090 · Travel and Lodging: $697 · Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,090.10 |
| Travel and Lodging | $697.03 |
| Food and Beverage | $672.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,891.07 | 2021-2025 | Davinci Xi, Da Vinci Surgical System |
| Shockwave Medical, INC | $150.47 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Ethicon US, LLC | $140.91 | 2025 | Stratafix, Echelon Flex, Dermabond |
| Baxter Healthcare | $125.00 | 2022 | |
| Tela Bio, INC. | $119.57 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Takeda Pharmaceuticals U.S.A., INC. | $110.17 | 2021 | |
| Heron Therapeutics, INC. | $109.62 | 2025 | Zynrelef |
| Davol INC. | $88.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $82.90 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Medtronic, INC. | $21.61 | 2023 | Gia |
| Boston Scientific Corporation | $20.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.